Savara Inc. (SVRA) Stock Price

SVRAStock

$4.45+24.30%52W

Market Cap$911.93M

P/E—

PEG Ratio—

Div yield—

Beta0.30

SVRA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-36.59%

Price vs S&P 500 (4W)-17.02%

VGM Score33.45

Book Value / Share (Quarterly)$0.70

P/TBV (Annual)6.41x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.54

Price vs S&P 500 (YTD)-38.13%

Net Profit Margin (TTM)-4253.85%

EPS (TTM)$-0.58

10-Day Avg Trading Volume2.32M

EPS Excl Extra (TTM)$-0.58

EPS (Annual)$-0.48

ROI (Annual)-48.47%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-11537.00%

Cash / Share (Quarterly)$0.84

ROA (Last FY)-45.10%

EBITD / Share (TTM)$-0.60

ROE (5Y Avg)-47.43%

Operating Margin (TTM)-4150.00%

Cash Flow / Share (Annual)$-0.49

P/B Ratio6.36x

P/B Ratio (Quarterly)8.79x

Net Income / Employee (Annual)$-1,371,400

EV / Revenue (TTM)3471.56x

Net Interest Coverage (TTM)-345.82x

ROA (TTM)-68.95%

EPS Incl Extra (Annual)$-0.48

Current Ratio (Annual)11.85x

Quick Ratio (Quarterly)10.00x

3-Month Avg Trading Volume1.91M

52-Week Price Return24.30%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.64

P/S Ratio (Annual)3516.53x

Asset Turnover (Annual)0.00x

52-Week High$7.00

Operating Margin (5Y Avg)-11595.18%

EPS Excl Extra (Annual)$-0.48

CapEx CAGR (5Y)-63.27%

Tangible BV CAGR (5Y)29.74%

26-Week Price Return-26.69%

Quick Ratio (Annual)11.68x

13-Week Price Return-19.38%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)10.13x

Enterprise Value$902.61M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-3.49%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-19084.62%

Cash / Share (Annual)$1.15

3-Month Return Std Dev43.74%

Net Income / Employee (TTM)$-1,990,100

ROE (Last FY)-55.99%

Net Interest Coverage (Annual)-18.37x

EPS Basic Excl Extra (Annual)$-0.48

Total Debt / Equity (Quarterly)0.21x

EPS Incl Extra (TTM)$-0.58

ROI (TTM)-75.60%

P/S Ratio (TTM)3516.53x

Pretax Margin (5Y Avg)-11907.77%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.94

Price vs S&P 500 (52W)8.77%

Year-to-Date Return-26.20%

5-Day Price Return-8.06%

EPS Normalized (Annual)$-0.48

ROA (5Y Avg)-35.67%

Net Profit Margin (Annual)-19084.62%

Month-to-Date Return-13.76%

Cash Flow / Share (TTM)$-0.31

EBITD / Share (Annual)$-0.52

Operating Margin (Annual)-18961.54%

LT Debt / Equity (Annual)0.15x

ROI (5Y Avg)-38.10%

LT Debt / Equity (Quarterly)0.21x

EPS Basic Excl Extra (TTM)$-0.58

P/TBV (Quarterly)9.54x

P/B Ratio (Annual)6.04x

Pretax Margin (TTM)-4253.85%

Book Value / Share (Annual)$0.99

Price vs S&P 500 (13W)-22.07%

Beta0.30x

Revenue / Share (TTM)$0.00

ROE (TTM)-90.28%

52-Week Low$3.50

vGradeF

mGradeC

vgmGradeD

SVRA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.15	-$0.16	-9.59%(-$0.01)
Q4 2025	Mar 13, 2026	-$0.12	-$0.13	-11.43%(-$0.01)
Q3 2025	Nov 12, 2025	-$0.13	-$0.14	-6.06%(-$0.01)
Q2 2025	Aug 13, 2025	-$0.12	-$0.14	-16.67%(-$0.02)

SVRA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SVRASavara Inc.	F	—	C	3516.5x	—	—	—	$4.45
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Savara Inc.

Savara Inc. is a specialty pharmaceutical company developing treatments for rare respiratory diseases. Its lead program, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

SVRA Next Earnings Report

Report dateNov 11, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.17

Revenue estimate$0

Also reporting on Nov 11, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

IMTXImmatics N.V. Ordinary SharesBiological Products
REPLReplimune Group, Inc.Biological Products
GPREGreen Plains, Inc.Industrial Chemicals
VORVor Biopharma Inc. Common StockBiological Products
MGTXMeiraGTx Holdings plc Ordinary SharesBiological Products
QDELQuidelOrtho Corporation Common StockIn Vitro Diagnostics
FMCFMC CorporationChemicals
FTKFlotek Industries, Inc.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$3.50

High$7.00